At LogiPharma USA 2026, Mark Talens explains where pharma gains the most from shared distribution visibility.

Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.

Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.

In this week's Pharma Pulse, Arkansas independent pharmacies bring an underpayment suit against Express Scripts, Novo Nordisk taps Anthropic for AI-driven drug discovery, and Sanofi, UCB and Opella join AstraZeneca on a supply chain heat decarbonization program.

At LogiPharma USA 2026, Cold Chain Technologies' TJ Rizzo explains how gaps in end-to-end cold chain expertise create risk for advanced therapies.

Octapharma USA's Kerem Tokel explains how tariffs and DSCSA are affecting how stolen pharma loads are resold, and why partner SOPs matter.

In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.

Freehand CEO Nitin Jayakrishnan explains why pharma manufacturers are trading long-term plans for operating models built to sense and pivot.